EUVIMEDEUVIMED entdecken
Open Access

Feasibility and Safety of Diffusing Alpha-Emitter Radiation Therapy for Recurrent or Unresectable Skin Cancers

Mark A D'Andrea, Noam A VanderWalde, Matthew T Ballo, Pradeep Patra, Gil'ad N Cohen, Antonio L Damato, Christopher A Barker

JAMA Network Open · 11.05.2023 · 6 (5) · e2312824

DOI: 10.1001/jamanetworkopen.2023.12824 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 11.05.2023. Verfasst von Mark A D'Andrea und 6 weiteren Autor:innen. Beteiligte Einrichtung: University Cancer Centers, Houston, Texas. Hauptthemen laut MEDLINE: Brachytherapy, Skin Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Patients with recurrent or unresectable skin cancers have limited treatment options. Diffusing alpha-emitter radiation therapy (DaRT), a novel solid tumor management strategy using alpha-particle interstitial brachytherapy, may address this challenge.

Objective

To evaluate the feasibility and safety of using DaRT to manage recurrent or unresectable skin cancers. Design, Setting, and Participants This prospective cohort study of patients who received a 2-week to 3-week treatment course and were followed up for 24 weeks after treatment during 2021 and 2022 at 2 sites in the US. Patients with malignant skin tumors or soft tissue tumors were recruited if they had limited treatment options for tumors recurrent after prior surgery or external beam radiotherapy or unresectable tumors.

Intervention

Patients underwent DaRT to deliver a physical dose of 10 Gy (equivalent weighted dose of 200 CGE) to the tumor. Main Outcomes and Measures Feasibility of the DaRT procedure was evaluated based on the ability of investigators to successfully deliver radiation to the tumor. Patients were followed up for adverse events (AEs) for 24 weeks and for tumor response by physicians’ physical examination and imaging 12 weeks after device removal.

Results

This study included 10 participants with recurrent or unresectable skin cancer (median [IQR] age, 72 [68-75] years; 6 males [60%]; 4 females [40%]). Six patients (60%) had recurrent disease, and 4 (40%) had tumors that were deemed unresectable. Tumors were located on the nose, chin, eyelid, scalp, neck, trunk, and extremities. Median (range) tumor volume before treatment was 2.1 cm 3 (0.65-12.65 cm 3 ). The mean (SD) prescription dose coverage of the gross tumor volume was 91% (2.8%) with all tumors having coverage of 85% or more. No device-related grade 3 AEs were noted. Common AEs were grade 1 to 2 erythema, edema, and pruritus. At 12 weeks following treatment, there was a 100% complete response rate. Nine of 10 complete responses (90%) were confirmed by CT imaging. Conclusions and Relevance This cohort study suggests the feasibility and preliminary safety of DaRT in the management of recurrent or unresectable skin cancers. The favorable safety profile and high response rates are promising. A US trial for marketing approval based on this pilot study is under way. Trial Registration ClinicalTrials.gov Identifier: NCT04377360

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BrachytherapySkin NeoplasmsMaleFemaleHumansAgedCohort StudiesProspective StudiesPilot ProjectsFeasibility Studies

Autor:innen und Institutionen

  • University Cancer Centers, Houston, Texas.
  • West Cancer Center, Germantown, Tennessee.
  • Memorial Sloan Kettering Cancer Center, New York, New York.

Förderung

  • NCI NIH HHS

Zitieren

APA

D'Andrea, M. A., VanderWalde, N. A., Ballo, M. T., Patra, P., Cohen, G. N., Damato, A. L., & Barker, C. A. (2023). Feasibility and Safety of Diffusing Alpha-Emitter Radiation Therapy for Recurrent or Unresectable Skin Cancers. JAMA Network Open, 6(5), e2312824. https://doi.org/10.1001/jamanetworkopen.2023.12824

Vancouver

D'Andrea MA, VanderWalde NA, Ballo MT, Patra P, Cohen GN, Damato AL, et al. Feasibility and Safety of Diffusing Alpha-Emitter Radiation Therapy for Recurrent or Unresectable Skin Cancers. JAMA Network Open. 2023;6(5):e2312824. doi:10.1001/jamanetworkopen.2023.12824

BibTeX
@article{DAndrea2023,
  author = {D'Andrea, Mark A and VanderWalde, Noam A and Ballo, Matthew T and Patra, Pradeep and Cohen, Gil'ad N and Damato, Antonio L and Barker, Christopher A},
  title = {Feasibility and Safety of Diffusing Alpha-Emitter Radiation Therapy for Recurrent or Unresectable Skin Cancers},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {5},
  pages = {e2312824},
  doi = {10.1001/jamanetworkopen.2023.12824}
}
Kostenlos starten →